CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-21 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Trump nevertheless urged his supporters on January 6 to march to the Capitol while the joint session of Congress was assembled there to count electoral votes and formalize Biden's victory, whereupon hundreds of people stormed the building and interrupted the count. During the attack, Biden addressed the nation, calling the events "an unprecedented assault unlike anything we've seen in modern times". After the Capitol was cleared, Congress officially counted the election results, with Pence, in his role as president of the Senate, announcing Biden and Harris as the winners. On January 7, Trump acknowledged the incoming administration without mentioning Biden's name.
== Psychology and neuroscience == Cannabis use in pregnancy is not low risk. The tetrahydrocannabinol (THC) within cannabis crosses the placenta, directly exposing the developing fetus to this chemical. Cannabis use in pregnancy is linked to increased risk of preterm delivery and lower birth weight, along with a higher likelihood of infants needing placement in the neonatal intensive care unit. Additionally, infants exposed to cannabis in pregnancy may have increased rates of behavioral conditions such as hyperactivity and impulsivity, attention deficits, sleep disorders, emotional disturbances, and a higher chance of substance use. According to a 2015 study, 70% of pregnant American women that had used marijuana in the past year thought that consumption of cannabis once or twice per week carried low to no risk of general harm. True photographic memory (the ability to remember endless images, particularly pages or numbers, with such a high degree of precision that the image mimics a photo) has never been demonstrated to exist in any individual, although a small number of young children have eidetic memory, where they can recall an object with high precision for a few minutes after it is no longer present. Many people have claimed to have a photographic memory, but those people have been shown to have high precision memories as a result of mnemonic devices rather than a natural capacity for detailed memory encoding. There are rare cases of individuals with exceptional memory, but none of them have a memory that mimics that of a camera.
Fibroblasts (reticular connective tissue) Macrophages, which contribute especially to red blood cell production by delivering iron for hemoglobin synthesis Adipocytes (fat cells) Osteoblasts (synthesize bone) Osteoclasts (resorb bone) Endothelial cells, which form the sinusoids. These are derived from endothelial stem cells, which are also present in the bone marrow.
Sources: en.wikipedia.org
=== Acidity/basicity === Ionic compounds containing hydrogen ions (H+) are classified as acids, and those containing electropositive cations and basic anions ions hydroxide (OH−) or oxide (O2−) are classified as bases. Other ionic compounds are known as salts and can be formed by acid–base reactions. Salts that produce hydroxide ions when dissolved in water are called alkali salts, and salts that produce hydrogen ions when dissolved in water are called acid salts, e.g. sodium hydrogen selenite (NaHSeO3). If the compound is the result of a reaction between a strong acid and a weak base, the result is an acid salt. If it is the result of a reaction between a strong base and a weak acid, the result is a base salt. If it is the result of a reaction between a strong acid and a strong base, the result is a neutral salt. Weak acids reacted with weak bases can produce ionic compounds with both the conjugate base ion and conjugate acid ion, such as ammonium acetate. Some ions are classed as amphoteric, being able to react with either an acid or a base. This is also true of some compounds with ionic character, typically oxides or hydroxides of less-electropositive metals (so the compound also has significant covalent character), such as zinc oxide, aluminium hydroxide, aluminium oxide and lead(II) oxide.
==== African education system ==== For African students primary school also lasted for 7 years. Around half of early primary students progressed to higher primary levels. and after finishing primary school if they chose to progress to secondary school had to take a test unlike their white counterparts. Secondary school lasted for 4 years but could be extended to 6. Most students did not make it to higher secondary levels.
==== MeSH D12.776.467.100.800 – vascular endothelial growth factors ==== MeSH D12.776.467.100.800.200 – vascular endothelial growth factor a MeSH D12.776.467.100.800.300 – vascular endothelial growth factor b MeSH D12.776.467.100.800.400 – vascular endothelial growth factor c MeSH D12.776.467.100.800.500 – vascular endothelial growth factor d MeSH D12.776.467.100.800.600 – vascular endothelial growth factor, endocrine-gland-derived
== History == Flutamide was first synthesized in 1967 by Neri and colleagues at Schering Plough Corporation. It was originally synthesized as a bacteriostatic agent, but was subsequently, and serendipitously found to possess antiandrogen activity. The code name of flutamide during development was SCH-13521. Clinical research of the medication began in 1971, and it was first marketed in 1983, specifically in Chile under the brand name Drogenil and in West Germany under the brand name Flugerel. Flutamide was not introduced in the United States until 1989; it was specifically approved by the U.S. Food and Drug Administration for the treatment of metastatic prostate cancer in combination with a gonadotropin-releasing hormone (GnRH) analogue. The medication was first studied for the treatment of hirsutism in women in 1989. It was the first "pure antiandrogen" to be studied in the treatment of hirsutism. Flutamide was the first NSAA to be introduced, and was followed by nilutamide in 1989 and then bicalutamide in 1995.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.